CRSPCRISPR keeps flexing the gene-editing muscle
CRISPR Therapeutics showed off late-breaking Phase 1a data for CTX310 at the ESC Congress 2026, and the update reads like a biotech pitch deck with receipts. The investigational therapy delivered a mean 79% reduction in circulating ANGPTL3, with triglycerides down 48% and LDL down 53% at the highest dose.
Why investors should care
That’s not just science fair bragging rights. If those lipid-lowering effects hold up in bigger studies, CTX310 could become a serious entrant in the cardiovascular market — the kind of program that can turn “interesting platform company” into “wait, maybe this thing is actually huge.”
The safety headline helped too:
- No treatment-related serious adverse events
- No Grade 3 or worse liver transaminase changes
- No new treatment-related adverse events since the last update
The durability part is the real sauce
The company says the effect was sustained through one year of follow-up, and the findings were published at the same time in The New England Journal of Medicine. In biotech land, durability is basically the difference between “cool demo” and “maybe a business.”
Big picture: CRISPR is still very much in the experimental phase here, but these data keep the CTX310 story alive and give investors another reason to watch the company’s cardiovascular pipeline instead of treating it like a one-trick editing pony.